Please login to the form below

Not currently logged in
Email:
Password:

Oramed completes USD 2m financing round

Oramed Pharmaceuticals, an Israeli-headquartered developer of oral insulin gel capsules, has closed a financing round of over USD 2m by private investors.

Oramed Pharmaceuticals, an Israeli-headquartered developer of oral insulin gel capsules, has closed a financing round of over USD 2m by private investors.

The placement was at USD 0.50 per share with a warrant priced at USD 0.75.

Oramed's CEO, Nadav Kidron, said: "This investment, at a premium to the market, ensures that Oramed has enough funds to reach completion of phase I trials, which we expect by mid-2008. We hope to complete our phase Ia trials shortly. This investment...allows the company to fully focus on its R&D efforts and complete its phase I product trials."

Oramed is currently developing an orally ingestible soft gel insulin capsule for the treatment of diabetes. The company says it is also pursuing the development of oral delivery solutions for other drugs and vaccines.

6th August 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics